Etiology and Prognostic Analysis of Acute Liver Failure in Chinese Children
NCT ID: NCT06778941
Last Updated: 2025-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
400 participants
OBSERVATIONAL
2025-02-01
2029-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pediatric acute liver failure (PALF) refers to the sudden onset of severe liver injury in children without known chronic liver disease, leading to multi-system organ dysfunction, with a mortality rate as high as 50%-70%. The etiology of PALF is complex and varied, including infections, metabolic disorders, and toxins. In developed countries, it is often caused by drug and toxin exposure, while in developing countries, viral infections are the primary cause. Additionally, 30%-50% of PALF cases have an unknown etiology, which increases the difficulty of treatment. Current treatment options include medical management, artificial liver support, and liver transplantation. Liver transplantation is the only proven effective treatment, but issues such as organ shortages and the timing of transplantation affect treatment outcomes. Improving diagnostic capabilities for the etiology and exploring optimal treatment strategies are of significant importance in enhancing the clinical success rate of PALF management.
Research Objective:
To explore the etiology and prognostic factors of pediatric acute liver failure (PALF), analyze the relationship between different causes of PALF and prognosis, and the relationship between different treatment modalities and prognosis. This study aims to investigate the correlation between etiology, treatment methods, and outcomes, providing scientific evidence to improve the precision in diagnosis and treatment of PALF and to enhance decision-making and timing judgments for liver transplantation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Pediatric Acute Liver Failure
NCT06893042
A Multi-Center Group to Study Acute Liver Failure in Children
NCT00986648
Prognosis of Patients With Acute-on-chronic Liver Failure
NCT05393453
Unknown Cause of Acute Liver Failure
NCT02041637
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
NCT03281265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Handling of lost to follow-up: Multiple contact information and emergency contacts were collected at the beginning of the study to maintain regular communication with the patients and their guardians to reduce the risk of lost follow-up. If follow-up failed, multiple attempts were made to contact participants via phone, email, or other methods. Once lost to follow-up, multiple imputation methods were used to estimate missing data, and sensitivity analyses were conducted (if possible).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Criteria for Diagnosing Pediatric Acute Liver Failure
This study is a multi-center, nationwide, dual-perspective, observational, open cohort study. It will recruit eligible hospitalized patients from the First Hospital of Jilin University and other participating institutions across the country for observation.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
① Severe biochemical liver abnormalities occurring within 8 weeks;
② Coagulation disorders uncorrectable by vitamin K: if hepatic encephalopathy is present, prothrombin time (PT) \> 15s or international normalized ratio (INR) \> 1.5; regardless of the presence of hepatic encephalopathy, PT \> 20s or INR \> 2.0.
2. For patients who were admitted twice, only the information from the first hospitalization will be used.
3. Patients with a history of chronic liver disease (e.g., genetic metabolic factors, drug-induced factors) or biliary obstruction that led to the acute episode are categorized under acute liver failure.
4. The child's legal guardian has signed a written informed consent form.
Exclusion Criteria
2. Significant data missing (\>10%);
3. The child's legal guardian refuses participation.
28 Days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
liyumei
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
liyumei
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChiCTR2400089260
Identifier Type: REGISTRY
Identifier Source: secondary_id
24K203-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.